Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Janssen Halts HCV Drug Development & Turns Efforts Towards Fighting HBV
Janssen announces a strategic decision to discontinue the development of investigational hepatitis C treatment, JNJ-4178, a triple-combination drug, consisting of three direct-acting antivirals.
Hepatic Steatosis Affects More HIV Patients without HCV Coinfection
Researchers elucidate the prevalence of hepatic steatosis in patients infected with HIV, as well as in patients coinfected with HIV and HCV.
Will Criminalizing Opioid Abuse Stop the Problem? Public Health Watch Report
This week we explore whether or not a national state of emergency and criminalizing opioid abuse will really help to stop the problem.
Sofosbuvir-Based Treatment Offers High SVR Rates in Hard-to-Treat HCV Genotype 3 Patients
A new study finds that sofosbuvir-based treatment in a real-life setting offered SVR rates greater than 90% in hard-to-treat HCV genotype 3 patients with advanced liver disease.
Age is No Longer a Barrier to Hepatitis C Treatment with Newer DAAs
A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.
Glecaprevir & Pibrentasvir Yield High Cure Rates in Non-cirrhotic Patients with HCV Genotype 1-6
A new study demonstrates that the drug regimen consisting of glecaprevir plus pibrentasvir for non-cirrhotic patients with HCV genotype 1-6 is safe and effective.
Treatment as Prevention: A Comprehensive Approach to Hepatitis C Virus in Persons Who Inject Drugs
With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.
Mavyret Approved for Patients with Chronic HCV Genotypes 1-6 Without Cirrhosis
The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.
Big advances in treatment can